Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report
- Authors:
- Yueqing Cao
- Lang Zou
- Hao Zhou
- Gan Fu
- Xielan Zhao
-
Affiliations: Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China - Published online on: July 5, 2022 https://doi.org/10.3892/ol.2022.13418
- Article Number: 298
-
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Al-Samkari H and Berliner N: Hemophagocytic lymphohistiocytosis. Annu Rev Pathol. 13:27–49. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yildiz H, Van Den Neste E, Defour JP, Danse E and Yombi JC: Adult haemophagocytic lymphohistiocytosis: A review. QJM. Jan 14–2020.(Epub ahead of print). PubMed/NCBI | |
|
Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, Hines M, Eckstein O, Ladisch S, Nichols KE, et al: Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American consortium for histiocytosis (NACHO). Pediatr Blood Cancer. 66:e279292019. View Article : Google Scholar : PubMed/NCBI | |
|
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Huang J and Zeng Q: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma. BMC Cancer. 20:12182020. View Article : Google Scholar : PubMed/NCBI | |
|
Sarkozy C and Sehn LH: Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 31:209–216. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, et al: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, et al: Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large b-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 35:2473–2481. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, et al: Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 37:1285–1295. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Denker S, Bittner A, Na IK, Kase J, Frick M, Anagnostopoulos I, Hummel M and Schmitt CA: A phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response. Int J Hematol Oncol. 8:IJH202019. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, Vermeulen J, Shreeve M and Staudt LM: Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 39:1643–1653.e3. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, et al: HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. HLH study GRoup of the histiocyte society. Med Pediatr Oncol. 28:342–347. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, et al: International myeloma working group molecular classification of multiple myeloma: Spotlight review. Leukemia. 23:2210–2221. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yohe S and Thyagarajan B: Review of clinical next-generation sequencing. Arch Pathol Lab Med. 141:1544–1557. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bartlett NL, Wilson WH, Jung SH, His ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, et al: Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 37:1790–1799. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Daudignon A, Quilichini B, Ameye G, Poirel H, Bastard C and Terré C: Cytogenetics in the management of multiple myeloma: An update by the groupe francophone de cytogénétique hématologique (GFCH). Ann Biol Clin (Paris). 74:588–595. 2016.PubMed/NCBI | |
|
Tian E: Fluorescence in situ hybridization (FISH) in multiple myeloma. Methods Mol Biol. 1792:55–69. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Campo M and Berliner N: Hemophagocytic lymphohistiocytosis in adults. Hematol Oncol Clin North Am. 29:915–925. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, et al: Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 133:2465–2477. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chang Y, Cui M, Fu X, Han L, Zhang L, Li L, Li X, Sun Z, Wu J, Zhang X, et al: Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. Oncol Lett. 16:1275–1284. 2018.PubMed/NCBI | |
|
Yu JT, Wang CY, Yang Y, Wang RC, Chang KH, Hwang WL and Teng CL: Lymphoma-associated hemophagocytic lymphohistiocytosis: Experience in adults from a single institution. Ann Hematol. 92:1529–1536. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Malkan UY, Albayrak M, Yildiz A, Maral S, Afacan Ozturk HB and Comert P: A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Oncol Pharm Pract. 27:250–252. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MS, Cho YU, Jang S, Seo EJ, Lee JH and Park CJ: A case of primary bone marrow diffuse large B-cell lymphoma presenting with fibrillar projections and hemophagocytic lymphohistiocytosis. Ann Lab Med. 37:544–546. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, He Y, Wang D, Hu Y, Wang W and Huang R: A case of diffuse large B-cell lymphoma complicated by hemophagocytic syndrome. Clin Lab. 60:681–683. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Davidson-Moncada JK, McDuffee E and Roschewski M: CD5+ diffuse large B-cell lymphoma with hemophagocytosis. J Clin Oncol. 31:e76–e79. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Desai A, Saul EE, Chapman JR, Lekakis L and Pimentel A: Adult lymphoma-associated hemophagocytic lymphohistiocytosis: A clinical case series in a predominantly hispanic cohort. J Med Cases. 11:256–261. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kwoun WJ, Ahn JY, Park PW, Seo YH, Kim KH, Seo JY, Lee HT and Yoo KH: How useful is bone marrow study as an initial investigative tool without lymph node biopsy in malignant lymphoma?: Eleven years of experience at a single institution. J Clin Lab Anal. 33:e228412019. View Article : Google Scholar : PubMed/NCBI | |
|
Chigrinova E, Mian M, Scandurra M, Greiner TC, Chan WC, Vose JM, Inghirami G, Chiappella A, Baldini L, Ponzoni M, et al: Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematol Oncol. 29:38–41. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pezzella F, Munson PJ, Miller KD, Goldstone AH and Gatter KC: The diagnosis of low-grade peripheral B-cell neoplasms in bone marrow trephines. Br J Haematol. 108:369–376. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
de Leval L and Harris NL: Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology. 43:509–528. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lin P, Molina TJ, Cook JR and Swerdlow SH: Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. Am J Clin Pathol. 136:195–210. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Boiza-Sánchez M, Manso R, Balagué O, Chamizo C, Askari E, Salgado RN, Blas-López C, Aguirregoicoa-García E, Menárguez J, Santonja C, et al: Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution? PLoS One. 15:e02416342020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W and Lin P: Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: Clinicopathological features and differential diagnosis. Pathology. 52:6–14. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ohno T, Ueda Y, Nagai K, Takahashi T, Konaka Y, Takamatsu T, Suzuki T, Sasada M and Uchiyama T; Kyoto University Hematology/Oncology Study Group, : The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: A comparative analysis of B-cell and T-cell/natural killer cell lymphomas. Int J Hematol. 77:286–294. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol. 3:745–756. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Pękalski J, Zuk PJ, Kochańczyk M, Junkin M, Kellogg R, Tay S and Lipniacki T: Spontaneous NF-κB activation by autocrine TNFα signaling: A computational analysis. PLoS One. 8:e788872013. View Article : Google Scholar : PubMed/NCBI | |
|
Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y and Kurokawa M: Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J Clin Invest. 124:528–542. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hayakawa K, Meng Y, Hiramatsu N, Kasai A, Yao J and Kitamura M: Spontaneous activation of the NF-kappaB signaling pathway in isolated normal glomeruli. Am J Physiol Renal Physiol. 291:F1169–F1176. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TK, Denny EM, Sanghvi JC, Gaston JE, Maynard ND, Hughey JJ and Covert MW: A noisy paracrine signal determines the cellular NF-kappaB response to lipopolysaccharide. Sci Signal. 2:ra652009. View Article : Google Scholar : PubMed/NCBI | |
|
Hashwah H, Bertram K, Stirm K, Stelling A, Wu CT, Kasser S, Manz MG, Theocharides AP, Tzankov A and Müller A: The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. EMBO Mol Med. 11:e105762019. View Article : Google Scholar : PubMed/NCBI | |
|
Hasnain SZ: Endoplasmic reticulum and oxidative stress in immunopathology: Understanding the crosstalk between cellular stress and inflammation. Clin Transl Immunology. 7:e10352018. View Article : Google Scholar : PubMed/NCBI | |
|
Nikesitch N, Lee JM, Ling S and Roberts TL: Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin Transl Immunology. 7:e10072018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HQ, Jia L, Li YT, Farren T, Agrawal SG and Liu FT: Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. J Cell Physiol. 234:13994–14006. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Knittel G, Liedgens P, Korovkina D, Pallasch CP and Reinhardt HC: Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. Eur J Haematol. 97:499–510. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 367:826–833. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Maamoun H, Abdelsalam SS, Zeidan A, Korashy HM and Agouni A: Endoplasmic reticulum stress: A critical molecular driver of endothelial dysfunction and cardiovascular disturbances associated with diabetes. Int J Mol Sci. 20:16582019. View Article : Google Scholar : PubMed/NCBI | |
|
Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 107:4907–4916. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Grondona P, Bucher P, Schulze-Osthoff K, Hailfinger S and Schmitt A: NF-κB activation in lymphoid malignancies: Genetics, signaling, and targeted therapy. Biomedicines. 6:382018. View Article : Google Scholar : PubMed/NCBI | |
|
Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, et al: Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 38:1198–1208. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Visco C, Tanasi I, Quaglia FM, Ferrarini I, Fraenza C and Krampera M: Oncogenic mutations of MYD88 and CD79B in diffuse large B-Cell lymphoma and implications for clinical practice. Cancers. 12:29132020. View Article : Google Scholar : PubMed/NCBI | |
|
Young RM and Staudt LM: Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 12:229–243. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RA, Schrader AM, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, et al: MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 105:424–434. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, et al: Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: Quality of life, dosing, and safety results from the randomised controlled REMARC study. Br J Haematol. 189:84–96. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 12:131–144. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM and Wilson WH: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 113:6069–6076. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, et al: Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An open-label, randomised, phase 3 trial. Lancet Oncol. 20:649–662. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tang S, Zhao C and Chen W: Aggressive diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: Report of one case. Int J Clin Exp Pathol. 13:2392–2396. 2020.PubMed/NCBI | |
|
Wu R, Deng X, Hao S and Ma L: Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: A case report. J Int Med Res. 48:3000605198822332020.PubMed/NCBI | |
|
Patel R, Patel H, Mulvoy W and Kapoor S: Diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis presenting as acute liver failure. ACG Case Rep J. 4:e682017. View Article : Google Scholar : PubMed/NCBI | |
|
Patel A, Vakiti A, Chilkulwar A and Mewawalla P: Hemophagocytic lymphohistiocytosis secondary to bone marrow only B-cell lymphoma: A very rare entity with an even rarer presentation. J Hematol. 6:49–51. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Entezari V, Agwa E, Ruiz SJ, Lietman SA, Silver BJ and Jegalian AG: Hemophagocytic lymphohistiocytosis secondary to localized large B-cell lymphoma in a patient with history of knee arthroplasty. Leuk Lymphoma. 56:1521–1523. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo CY, Yeh ST, Huang CT and Lin SF: Diffuse large B-cell lymphoma presenting with type B lactic acidosis and hemophagocytic syndrome. Kaohsiung J Med. 30:428–429. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Zhang XH, Zhou YL and Yin XL: Hemophagocyte lymphohistiocytosis secondary to bilateral epididymal diffuse large B-cell lymphoma. Indian J Hematol Blood Transfus. 30 (Suppl 1):S93–S96. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sano T, Sakai H, Takimoto K and Ohno H: Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome. Int J Clin Oncol. 12:59–62. 2007. View Article : Google Scholar : PubMed/NCBI |
